Profil
Albert Paszek's former job positions include Senior Director-Manufacturing & Operations at Abeona Therapeutics, Inc., Senior Director-Technical Services at Alexion Pharmaceuticals, Inc., Senior Director & Site Head at Synageva BioPharma Corp., and Vice President-Manufacturing Science & Technology at Mustang Bio, Inc. He obtained a doctorate degree from the University of Minnesota.
Anciens postes connus de Albert Paszek
| Sociétés | Poste | Fin |
|---|---|---|
| MUSTANG BIO, INC. | Directeur Technique/Scientifique/R&D | 10/10/2023 |
| ALEXION PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/08/2017 |
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | - |
| ABEONA THERAPEUTICS INC. | Corporate Officer/Principal | - |
Formation de Albert Paszek
| University of Minnesota | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MUSTANG BIO, INC. | Health Technology |
| ABEONA THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
